Rein Therapeutics
RNTX
32 hedge funds and large institutions have $16.3M invested in Rein Therapeutics in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
21% more capital invested
Capital invested by funds: $13.5M → $16.3M (+$2.79M)
10% more funds holding
Funds holding: 29 → 32 (+3)
1.42% less ownership
Funds ownership: 22.67% → 21.25% (-1.4%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$286K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$230K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$159K |
| 4 |
GS
Gagnon Securities
New York
|
+$90.3K |
| 5 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
+$66.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$1M |
| 2 |
KC
Kepos Capital
New York
|
-$294K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$198K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$140K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$57.1K |
RNTX Hedge Fund Activity: Q3 2024 in Review
32 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2024, worth a combined $16.3M — up 21% from $13.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new RNTX positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Prosight Management, adding an estimated $286K. The largest seller was University of Texas/Texas AM Investment Management Co (UTIMCO), cutting an estimated $1M.
- 32 institutional investors held Rein Therapeutics (RNTX) as of Q3 2024, up from 29 in Q2 2024.
- Funds reported $16.3M of Rein Therapeutics stock for Q3 2024, up 21% quarter-over-quarter.
- 5 funds opened new Rein Therapeutics positions in Q3 2024 and 2 closed out, a net change of +3 holders.
- The largest Rein Therapeutics buyer in Q3 2024 was Prosight Management, an estimated $286K added.
- The largest Rein Therapeutics seller in Q3 2024 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $1M sold.
Based on aggregated 13F filings for Q3 2024.